AcelRx Pharmaceuticals, a California-based company specializing in pharmaceuticals, is dedicated to developing and commercializing therapies that target acute pain. Its primary focus is on DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet designed to treat moderate-to-severe acute pain. The company also has several other product candidates in development, including ZALVISO, a patient-controlled analgesia system, and ARX-02 and ARX-03, both of which are undergoing Phase 2 clinical trials. AcelRx's comprehensive product lineup also includes Niyad and LTX-608, which are anticoagulant and antiviral treatments, respectively. Additionally, the company is exploring the development of Fedsyra and phenylephrine, pre-filled syringes containing ephedrine and phenylephrine, respectively. AcelRx Pharmaceuticals was first established in 2005 as SuRx before changing its name in 2006. The company's headquarters are located in Hayward, California.